newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 awarded third year of funding from Gates Foundation AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today